Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology
April 26, 2021
Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure…
Read More
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
April 22, 2021
Advice For Hospitals Starting a Structural Heart Program
The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural…
Read More
The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.
April 21, 2021
FDA Clears SiteSeal SV Vascular Closure Device for the Brachial Arteries
April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market…
Read More
April 20, 2021
North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms
April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the…
Read More
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.
April 20, 2021
Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational…
Read More
Former Vice President Mike Pence. Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs
April 19, 2021
Former Vice President Mike Pence Has Pacemaker Implanted
April 19, 2021 — Former Vice President Mike Pence is recovering after having a pacemaker successfully implanted to…
Read More
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
April 19, 2021
Gene Therapy for Atrial Fibrillation Will Be Investigated With $3.67 million NIH Grant
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm…
Read More
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.
April 14, 2021
First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized…
Read More
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers. 
April 14, 2021
FDA Clears Acutus Medical AcQCross Suite of Transseptal Crossing Devices
April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal…
Read More
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
By Dave Fornell, Editor
April 13, 2021
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots
(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug…
Read More
Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT-D) devices because of an unexpected and rapid decrease in battery life. The company said this is due to a short circuit and will cause some devices to produce a “Recommended Replacement Time” (first warning that the battery is low) earlier than expected. Some devices may progress from “Recommended Replacement Time” to full battery depletion within as little as one day.
April 12, 2021
Medtronic Recalls its ICDs and CRT-Ds Due to Risk of Rapid Battery Depletion
April 12, 2021 — Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac…
Read More
The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).
April 08, 2021
Abbott Receives CE Mark and Canadian Approval for Next-Generation TriClip Tricuspid Valve Repair Device
April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for…
Read More
A reconstructed vessel segment from a cone-beam CT created table side in the cath lab with the Philips Azurion SmartCT software.
April 07, 2021
Philips SmartCT Enables 3D Image Acquisition in the Cath Lab
April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips…
Read More
The Stereotaxis Genesis Robotic Magnetic Navigation system.
April 07, 2021
Broward Health Medical Center First in Florida to Adopt Robotic Ablation Technology to Treat Arrhythmias
April 7, 2021 — Stereotaxis announced that Broward Health Medical Center is establishing a robotic electrophysiology (…
Read More
Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.
April 07, 2021
Thrombectomy Market Will Grow With Newly Approved Adjustable Stent Retriever
April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices),…
Read More
COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.
April 07, 2021
Tsunami of Chronic Health Conditions Expected Due to COVID-19 Disruption of Healthcare
April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially…
Read More
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 
April 06, 2021
Abbott’s Xience Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual…
Read More
The Acutus Medical AcQBlate Force sensing ablation catheter.
April 05, 2021
Acutus Medical Initiates First IDE Therapy Trial With AcQBlate Force Sensing Ablation System
April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter…
Read More
The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.
April 05, 2021
Heart in a Box Technology Expands Heart Transplant Window
April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to…
Read More
The new ACC Electrophysiology (EP) Device Implant Registry, part of the National Cardiovascular Data Registry (NCDR) will include data on implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) procedures previously captured in the NCDR ICD Registry, as well as provide the flexibility to capture novel pacemaker procedures. The registry is aligned with the ACC’s Electrophysiology Accreditation program, fully supporting the program’s data requirements.
April 02, 2021
ACC Launches NCDR Electrophysiology Device Implant Registry
April 2, 2021 — Today, the American College of Cardiology (ACC) launched the Electrophysiology (EP) Device Implant…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now